Your session is about to expire
← Back to Search
Immunotherapy + Chemotherapy for Lung Cancer (POSEIDON Trial)
POSEIDON Trial Summary
This trial is testing two different ways to treat lung cancer that has spread, one with two immunotherapy drugs and one with just one immunotherapy drug, compared to just using chemotherapy drugs.
POSEIDON Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowPOSEIDON Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.POSEIDON Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My brain or spinal cord cancer is stable without needing steroids.My lung cancer is confirmed to be at stage IV.I have never received immune therapy, except for cancer vaccines.My tumor's PD-L1 status has been confirmed.I have or had an autoimmune or inflammatory disorder.My cancer does not have EGFR mutations or ALK fusions.I am fully active or can carry out light work.I have not received any treatment for my advanced lung cancer.I do not have active infections like TB, hepatitis B, hepatitis C, or HIV.I am 18 years old or older.My lung cancer is a mix of small-cell and non-small cell types.
- Group 1: Treatment Arm 1
- Group 2: Treatment Arm 2
- Group 3: Treatment Arm 3
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
The inclusion criteria for this research project restricts it to those under 35, correct?
"This study is only taking applications from people aged 18-130. There are 183 other trials for people under 18 and 4002 for those over 65."
Could you please explain the possible negative effects of Durvalumab?
"There is both pre-existing efficacy data and multiple rounds of safety data supporting the use of Durvalumab, so it received a score of 3."
Are there any prerequisites to joining this clinical trial?
"This particular clinical trial is only enrolling patients that have lung cancer and are between 18-130 years old--1193 in total."
What are the common reasons that people are prescribed Durvalumab?
"Durvalumab is indicated for various conditions, including urothelial carcinoma, lymphoma, and non-small cell lung cancer."
Share this study with friends
Copy Link
Messenger